Tag #Glp-1

Showing 13 to 24 of 31 results

dailymail.co.uk

🌐 85% Global Worthiness

Jul 3, 16:14

Failure to Conduct Blood Tests Before Prescribing Mounjaro Risks Deadly Organ Failure for Thousands

A nurse warned that thousands of NHS patients using the weight-loss jab Mounjaro are at risk of deadly organ failure because GPs are not conducting mandatory blood tests to screen for underlying health issues that could worsen the drug's side effects, including pancreatitis and severe dehydration, b...

Failure to Conduct Blood Tests Before Prescribing Mounjaro Risks Deadly Organ Failure for Thousands

A nurse warned that thousands of NHS patients using the weight-loss jab Mounjaro are at risk of deadly organ failure because GPs are not conducting mandatory blood tests to screen for underlying health issues that could worsen the drug's side effects, including pancreatitis and severe dehydration, b...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of GPs failing to perform blood tests before prescribing Mounjaro, and what is the potential impact on patients?

Thousands of patients using the weight-loss injection Mounjaro may be at risk of deadly organ failure due to GPs' failure to conduct mandatory blood tests before prescribing the drug. These tests can detect underlying conditions like high triglycerides, which increase pancreatitis risk, and uncontrolled diabetes, increasing severe dehydration risk. Both conditions can lead to organ failure.

cincodias.elpais.com

🌐 85% Global Worthiness

Jun 21, 04:14

Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk

Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...

Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk

Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key safety considerations and adverse effects observed in the STEP UP trial related to the 7.2mg semaglutide dose?

Novo Nordisk's findings demonstrate a substantial increase in weight loss compared to lower semaglutide dosages, supporting the drug's efficacy in managing obesity. Even accounting for adherence, participants using 7.2mg semaglutide lost an average of 18.7% of their weight, significantly exceeding placebo results. This reinforces semaglutide's benefits beyond previous indications.

nos.nl

🌐 85% Global Worthiness

Jun 1, 01:10

UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market

In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...

UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market

In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the existence of a black market for weight-loss medication affect healthcare systems in the UK, particularly concerning patient safety and the appropriate use of these drugs?

The high prevalence of obesity in the UK (one in four with obesity, almost two-thirds overweight) fuels demand for these medications, creating both opportunities and risks. While the drugs show promise in reducing healthcare costs and boosting the economy, the unregulated market poses significant safety concerns.

kathimerini.gr

🌐 75% Global Worthiness

May 23, 22:10

Weight Regain After Stopping Weight-Loss Injections: An Oxford Study

A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.

Weight Regain After Stopping Weight-Loss Injections: An Oxford Study

A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the effects of older and newer weight-loss injections differ in terms of weight regain after treatment cessation?

The Oxford study highlights the importance of lifestyle changes alongside medication for sustainable weight loss. While injections effectively suppress appetite and promote weight loss, their cessation often leads to weight regain due to the return of normal hunger sensations. This underscores the need for comprehensive weight management programs.

bbc.com

🌐 75% Global Worthiness

May 12, 13:10

Weight Loss Injections' Rise Contributes to Weight Watchers' Bankruptcy

Simon, 34, lost 26 kg using Monjaro weight loss injections after years of failed dieting, including with Weight Watchers which has lost over a million members and filed for bankruptcy amid the rise of weight loss injections and social media.

Weight Loss Injections' Rise Contributes to Weight Watchers' Bankruptcy

Simon, 34, lost 26 kg using Monjaro weight loss injections after years of failed dieting, including with Weight Watchers which has lost over a million members and filed for bankruptcy amid the rise of weight loss injections and social media.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Simon's experience with Weight Watchers and Monjaro highlight the changing landscape of weight loss strategies?

Simon's story highlights the shift in weight loss strategies, from traditional programs like Weight Watchers to the use of weight-loss injections. Weight Watchers, once a dominant force with 4.5 million users, has lost over a million members and filed for bankruptcy, partly due to the rise in popularity of weight loss injections and social media.

nbcnews.com

🌐 90% Global Worthiness

May 1, 01:17

Wegovy Shows Promise in Treating Serious Liver Disease

A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.

Wegovy Shows Promise in Treating Serious Liver Disease

A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of Wegovy's efficacy in treating MASH, including the potential for relapse, durability of effects, and the need for continued medication?

The FDA's priority review of Wegovy for MASH, with a decision expected by year's end, signifies a potential paradigm shift in treating this prevalent liver disease. However, long-term studies are crucial to assess the durability of these improvements and determine whether the treatment translates to reduced long-term liver complications and mortality. The cost and potential side effects, primarily gastrointestinal issues, also warrant careful consideration.

elpais.com

🌐 75% Global Worthiness

Jul 3, 07:15

MHRA Investigates Link Between GLP-1 Drugs and Pancreatitis

The UK's MHRA is investigating a possible link between GLP-1 weight-loss drugs and pancreatitis, prompting a review of 560 cases, although current data doesn't indicate rates exceeding those in clinical trials; experts warn against unregulated use.

MHRA Investigates Link Between GLP-1 Drugs and Pancreatitis

The UK's MHRA is investigating a possible link between GLP-1 weight-loss drugs and pancreatitis, prompting a review of 560 cases, although current data doesn't indicate rates exceeding those in clinical trials; experts warn against unregulated use.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the UK MHRA's investigation into the link between GLP-1 drugs and pancreatitis?

The UK's MHRA is investigating a potential link between GLP-1 receptor agonists (like Ozempic) and pancreatitis, prompting a review of 560 pancreatitis cases in users. While the investigation is ongoing, preliminary data doesn't show pancreatitis rates exceeding those observed in clinical trials (less than 0.5% for semaglutide).

theguardian.com

🌐 75% Global Worthiness

Jun 5, 10:14

MHRA Warns of Pregnancy Risk with Weight-Loss Drugs

The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.

MHRA Warns of Pregnancy Risk with Weight-Loss Drugs

The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential mechanisms by which weight-loss drugs may affect contraceptive effectiveness, and what types of contraception are recommended?

The MHRA's warning highlights a potential interaction between weight-loss drugs and oral contraceptives, particularly Mounjaro, which may reduce their effectiveness in overweight individuals. The increase in pregnancies reported among users suggests a need for clearer communication about contraception alongside these medications. The agency also notes that obesity itself can impact fertility, potentially increasing the chance of pregnancy.

foxnews.com

🌐 85% Global Worthiness

May 26, 13:11

Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial

A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...

Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial

A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the dual mechanism of action of tirzepatide contribute to its superior weight-loss efficacy compared to semaglutide?

The study's findings align with independent trials of each drug, confirming tirzepatide's superior efficacy. The greater weight loss with tirzepatide (mimicking GLP-1 and GIP hormones) compared to semaglutide (mimicking only GLP-1) highlights the potential benefits of dual-hormone mechanisms in obesity treatment. These results provide crucial data for doctors, insurers, and patients seeking effective weight-loss options.

cnnespanol.cnn.com

🌐 85% Global Worthiness

May 22, 07:12

FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands

The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.

FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands

The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the underlying causes of the GLP-1 drug shortage, and how do insurance policies affect patient access?

The decision connects to broader concerns about drug pricing and accessibility. Compounded GLP-1 medications offered a lower-cost option, but lacked FDA approval, raising safety concerns. The ban could exacerbate existing shortages and increase pressure on brand-name drug supplies.

forbes.com

🌐 85% Global Worthiness

May 6, 01:16

CVS Drops Eli Lilly's Zepbound from Preferred Formulary

CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.

CVS Drops Eli Lilly's Zepbound from Preferred Formulary

CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of CVS Health's decision to remove Zepbound from its preferred formulary on patient access and affordability?

CVS Health will remove Eli Lilly's weight-loss drug, Zepbound, from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy instead. This impacts 90 million CVS Caremark members, potentially limiting Zepbound access or increasing out-of-pocket costs for many. Lilly is mitigating this by offering Zepbound through its own direct-to-consumer pharmacy and telehealth partnerships, bypassing traditional gatekeepers.

forbes.com

🌐 85% Global Worthiness

Feb 13, 16:08

GLP-1 Drugs: Reshaping Beauty Standards and Social Status

The increasing availability of GLP-1 weight-loss drugs is disrupting traditional beauty standards, potentially diminishing the status associated with thinness and prompting the affluent to seek new markers of distinction.

GLP-1 Drugs: Reshaping Beauty Standards and Social Status

The increasing availability of GLP-1 weight-loss drugs is disrupting traditional beauty standards, potentially diminishing the status associated with thinness and prompting the affluent to seek new markers of distinction.

Progress

52% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

How are GLP-1 weight-loss drugs reshaping societal beauty standards and perceptions of status?

The rising demand for GLP-1 weight-loss drugs like Ozempic and Wegovy is significantly altering beauty standards. Historically, thinness has correlated with status, but these drugs are making thinness more accessible, potentially diminishing its value as a status symbol. This democratization could lead to a shift in what constitutes desirable body image, particularly among those with greater means.

Showing 13 to 24 of 31 results